The apparent protective association we observe with prostate cancer risk is in line with the results from multiple phase I/II trials of TNFRSF10B agonists that support their use for the treatment of multiple cancer endpoints, though not yet including prostate cancer.60, 61, 62. This evidence concerns the gene TNFRSF10B and prostate carcinoma.